ReviewTranslational andrology and urology2017
Multi-parametric magnetic resonance imaging as a management decision tool.
Review in Translational andrology and urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Partial prostatectomy in prostate cancer: a systematic review of current evidence.Clinics (Sao Paulo, Brazil)Pooled it
- Prospective evaluation ofEuropean journal of nuclear medicine and molecular imaging · 2018Trial
- Local staging of de novo prostate cancer using mpMRI, PSMA-PET and PSMA-PET/mpMRI - a comparative study.EJNMMI research · 2025Article
- The utility of prostate MRI within active surveillance: description of the evidence.World journal of urology · 2022Review
- Review
- How Would MRI-targeted Prostate Biopsy Alter Radiation Therapy Approaches in Treating Prostate Cancer?Urology · 2018Article
- Exploration of the diagnostic value and molecular mechanism of miR‑1 in prostate cancer: A study based on meta‑analyses and bioinformatics.Molecular medicine reports · 2018Article
- Role of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Assessment.Acta clinica Croatica · 2018Review
- Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI.ACS medicinal chemistry letters · 2018Article
- Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions.Turkish journal of urology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to image the prostate accurately and better characterize cancerous lesions makes multiparametric magnetic resonance imaging (mpMRI) an invaluable tool to improve management of localized prostate cancer (PCa). Improved risk stratification is warranted given the evidence of significant overtreatment of indolent PCa. mpMRI can more accurately rule out clinically significant PCa in men deciding between surveillance and definitive treatment to reduce overtreatment. mpMRI improves detection of clinically significant PCa, which helps minimize sampling error, a major limitation of the traditional diagnostic paradigm. Aside from helping determine candidacy for initial surveillance
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.